Amy Wagelie-Steffen, MD
Allergy/ Immunology · Tucson, AZNPI 1467485169
Payments from drug & device makers
Across 936 payments — averaging $745.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$460K
- Regeneron Healthcare Solutions, Inc.$94K
- Sanofi$70K
- Genentech USA, Inc.$38K
- Amgen$19K
- Genentech, Inc.$4K
- plus $13K from 30 others
What the payments were for
- Consulting fees$60,5019%
- Speaking & faculty fees$567,08081%
- Travel & lodging$47,3567%
- Food & beverage$22,4603%
- Education$2940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 472 | $459,745 |
| Regeneron Healthcare Solutions, Inc. | 157 | $94,034 |
| Sanofi | 73 | $70,247 |
| Genentech USA, Inc. | 42 | $37,751 |
| Amgen | 60 | $19,255 |
| Genentech, Inc. | 1 | $4,050 |
| Pharming Healthcare, Inc. | 11 | $2,597 |
| Regeneron | 2 | $2,442 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $2,048 |
| Biocryst US Sales Co., LLC | 12 | $1,423 |
| Novartis | 22 | $1,230 |
| Biocryst Pharmaceuticals, Inc. | 1 | $1,125 |
| Optinose US, Inc. | 6 | $325 |
| GSK | 20 | $308 |
| CSL Behring | 10 | $247 |
| Shire North American Group Inc | 3 | $134 |
| Grifols USA, LLC | 4 | $78 |
| Kaleo, Inc. | 3 | $70 |
| Sanofi-aventis U.S. LLC | 1 | $65 |
| Dermavant Sciences, Inc. | 1 | $60 |
| Blueprint Medicines Corporation | 3 | $60 |
| Octapharma USA, Inc. | 1 | $55 |
| ADMA Biomanufacturing LLC | 4 | $42 |
| Pfizer | 2 | $36 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $36 |
| Jubilant Hollisterstier LLC | 2 | $30 |
| Boehringer Ingelheim | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Viatris Specialty LLC | 1 | $25 |
| Mylan Specialty L.p. | 1 | $24 |
| Bio Products Laboratory USA, Inc. | 2 | $24 |
| Ionis Pharmaceuticals, Inc. | 1 | $17 |
| Cycle Pharmaceuticals Inc | 1 | $16 |
| Incyte Corporation | 1 | $16 |
| Galderma Laboratories, L.p. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy/ immunology providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 28 | $1,416,065 |
| XolairOmalizumab | 156 | $460,369 |
| TezspireTezepelumab-Ekko | 86 | $358,738 |
| RuconestC1 Esterase Inhibitor, Recomb | 11 | $342,210 |
| IcatibantIcatibant Acetate | 16 | $228,607 |
| Dupixent SyringeDupilumab | 40 | $152,561 |
| Dupixent PenDupilumab | 16 | $87,219 |
| Fasenra PenBenralizumab | 14 | $81,463 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 85 | $69,078 |
| Spiriva RespimatTiotropium Bromide | 57 | $51,162 |
| Breo ElliptaFluticasone/Vilanterol | 78 | $46,335 |
| SymbicortBudesonide/Formoterol Fumarate | 67 | $19,687 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $14,972 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $12,599 |
| AirsupraAlbuterol Sulfate/Budesonide | 12 | $10,103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $2,048 | $1,416,06528 claims |
| Genentech, Inc.Xolair | $4,050 | $460,369156 claims |
| AstraZenecaTezspire, Symbicort, Breztri Aerosphere, Airsupra | $459,745 | $401,127179 claims |
| Pharming Healthcare, Inc.Ruconest | $2,597 | $342,21011 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $308 | $123,492185 claims |
| Boehringer IngelheimSpiriva Respimat | $27 | $51,16257 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy/ immunology providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other allergy/ immunology in Tucson
- Radha RishiChandler$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.